These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 30994574)

  • 21. Treatment utilization and non-drug interventions for vasomotor symptoms in breast cancer survivors taking endocrine therapy: Real-world findings from the United States and Europe.
    Kingsberg S; Banks V; Caetano C; Janssenswillen C; Moeller C; Schoof N; Harvey M; Scott M; Nappi RE
    Maturitas; 2024 Oct; 188():108071. PubMed ID: 39059108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Management of side effects related to adjuvant hormone therapy in young women with breast cancer].
    Saghatchian M; Lesur A
    Bull Cancer; 2019 Dec; 106(12S1):S37-S42. PubMed ID: 32008736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy.
    Ribi K; Luo W; Walley BA; Burstein HJ; Chirgwin J; Ansari RH; Salim M; van der Westhuizen A; Abdi E; Francis PA; Chia S; Harvey VJ; Giobbie-Hurder A; Fleming GF; Pagani O; Di Leo A; Colleoni M; Gelber RD; Goldhirsch A; Coates AS; Regan MM; Bernhard J
    Breast Cancer Res Treat; 2020 Jun; 181(2):347-359. PubMed ID: 32274665
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer.
    Fallowfield LJ; Bliss JM; Porter LS; Price MH; Snowdon CF; Jones SE; Coombes RC; Hall E
    J Clin Oncol; 2006 Feb; 24(6):910-7. PubMed ID: 16484701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How does adjuvant chemotherapy affect menopausal symptoms, sexual function, and quality of life after breast cancer?
    Marino JL; Saunders CM; Emery LI; Green H; Doherty DA; Hickey M
    Menopause; 2016 Sep; 23(9):1000-8. PubMed ID: 27272225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utilization of gynecologic services in women with breast cancer receiving hormonal therapy.
    Wright JD; Desai VB; Chen L; Burke WM; Tergas AI; Hou JY; Accordino M; Ananth CV; Neugut AI; Hershman DL
    Am J Obstet Gynecol; 2017 Jul; 217(1):59.e1-59.e12. PubMed ID: 28341383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
    Gradishar WJ
    Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Health-related quality of life in early breast cancer.
    Groenvold M
    Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sexual Dysfunction in Survivorship; the Impact of Menopause and Endocrine Therapy.
    Kuehn R; Casaubon J; Raker C; Edmonson D; Stuckey A; Gass J
    Ann Surg Oncol; 2019 Oct; 26(10):3159-3165. PubMed ID: 31342358
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A telehealth intervention for symptom management, distress, and adherence to adjuvant endocrine therapy: A randomized controlled trial.
    Jacobs JM; Post K; Massad K; Horick NK; Walsh EA; Cohn J; Rapoport CS; Clara AJ; Antoni MH; Safren SA; Partridge AH; Peppercorn JM; Park ER; Temel JS; Greer JA
    Cancer; 2022 Oct; 128(19):3541-3551. PubMed ID: 35924869
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tamoxifen effects on subjective and psychosexual well-being, in a randomised breast cancer study comparing high-dose and standard-dose chemotherapy.
    Mourits MJ; Böckermann I; de Vries EG; van der Zee AG; ten Hoor KA; van der Graaf WT; Sluiter WJ; Willemse PH
    Br J Cancer; 2002 May; 86(10):1546-50. PubMed ID: 12085202
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B.
    Fallowfield LJ; Leaity SK; Howell A; Benson S; Cella D
    Breast Cancer Res Treat; 1999 May; 55(2):189-99. PubMed ID: 10481946
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adherence to adjuvant tamoxifen and associated factors in breast cancer survivors.
    Uslu Y; Kocatepe V; Sezgin DS; Uras C
    Support Care Cancer; 2023 Apr; 31(5):285. PubMed ID: 37079089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer.
    Kyvernitakis I; Ziller V; Hars O; Bauer M; Kalder M; Hadji P
    Climacteric; 2014 Jun; 17(3):252-9. PubMed ID: 23805799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer.
    Baumgart J; Nilsson K; Stavreus-Evers A; Kask K; Villman K; Lindman H; Kallak T; Sundström-Poromaa I
    Am J Obstet Gynecol; 2011 Jan; 204(1):26.e1-7. PubMed ID: 20950790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Uterine and quality of life changes in postmenopausal women with an asymptomatic tamoxifen-thickened endometrium randomized to continuation of tamoxifen or switching to anastrozole.
    Van Calster B; Van Ginderachter J; Vlasselaer J; Van de Putte G; Berteloot P; Timmerman D; Depypere H; Blomme C; Vlaemynck G; De Jonge E; Van den Broecke R; Vergote I; Amant F; Van Huffel S; Neven P
    Menopause; 2011 Feb; 18(2):224-9. PubMed ID: 20881891
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sexuality and quality of life in women with a prior diagnosis of breast cancer after risk-reducing salpingo-oophorectomy.
    Tucker PE; Saunders C; Bulsara MK; Tan JJ; Salfinger SG; Green H; Cohen PA
    Breast; 2016 Dec; 30():26-31. PubMed ID: 27592287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A pilot randomized trial to prevent sexual dysfunction in postmenopausal breast cancer survivors starting adjuvant aromatase inhibitor therapy.
    Advani P; Brewster AM; Baum GP; Schover LR
    J Cancer Surviv; 2017 Aug; 11(4):477-485. PubMed ID: 28229275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Perspectives of postmenopausal breast cancer survivors on adjuvant endocrine therapy-related symptoms.
    van Londen GJ; Donovan HS; Beckjord EB; Cardy AL; Bovbjerg DH; Davidson NE; Morse JQ; Switzer GE; Verdonck-de Leeuw IM; Dew MA
    Oncol Nurs Forum; 2014 Nov; 41(6):660-8. PubMed ID: 25355021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.